Home >> Life Sciences >> Pharmaceuticals

Global Artemisinin Market Research Report Forecast 2017-2021

Published: Mar-2017 | Format: PDF | S&P Consulting | Number of pages: 122 | Code: MRS - 140090

The Global Artemisinin Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Artemisinin industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Artemisinin market study provides comprehensive data which enhances the understanding, scope and application of this report.
This report provides comprehensive analysis of
Key market segments and sub-segments
Evolving market trends and dynamics
Changing supply and demand scenarios
Quantifying market opportunities through market sizing and market forecasting
Tracking current trends/opportunities/challenges
Competitive insights
Opportunity mapping in terms of technological breakthroughs

Global Artemisinin Market: Regional Segment Analysis
North America
Europe
China
Japan
Southeast Asia
India

The Major players reported in the market include:
Sanofi
KPC Pharmaceuticals, Inc
Guangxi xiancaotang pharmaceutical Co., LTD
Guilin Pharmaceutical Co., Ltd
Kerui nanhai Pharmaceutical Co., Ltd
Shanghai Natural Bio-engineering Co., Ltd
PIDI Standard
Novanat Bioresource Co., Ltd
CATKHANH CO., Ltd
...

Global Artemisinin Market: Product Segment Analysis
Extraction from Artemisia annua
Extraction from engineered organisms
Type 3 
 

Global Artemisinin Market: Application Segment Analysis
Antimalarial Injections
Antimalarial Tablets
Application 3 

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth 
It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
Global Artemisinin Market Research Report Forecast 2017-2021

Chapter 1 Artemisinin Market Overview
1.1 Product Overview and Scope of Artemisinin
1.2 Artemisinin Market Segmentation by Type
1.2.1 Global Production Market Share of Artemisinin by Type in 2015
1.2.1 Extraction from Artemisia annua
1.2.2 Extraction from engineered organisms
1.2.3 Type 3
1.3 Artemisinin Market Segmentation by Application
1.3.1 Artemisinin Consumption Market Share by Application in 2015
1.3.2 Antimalarial Injections 
1.3.3 Antimalarial Tablets
1.3.4 Application 3
1.4 Artemisinin Market Segmentation by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India
1.5 Global Market Size (Value) of Artemisinin (2012-2021)

Chapter 2 Global Economic Impact on Artemisinin Industry
2.1 Global Macroeconomic Environment Analysis
2.1.1 Global Macroeconomic Analysis
2.1.2 Global Macroeconomic Environment Development Trend
2.2 Global Macroeconomic Environment Analysis by Regions

Chapter 3 Global Artemisinin Market Competition by Manufacturers
3.1 Global Artemisinin Production and Share by Manufacturers (2015 and 2016)
3.2 Global Artemisinin Revenue and Share by Manufacturers (2015 and 2016)
3.3 Global Artemisinin Average Price by Manufacturers (2015 and 2016)
3.4 Manufacturers Artemisinin Manufacturing Base Distribution, Production Area and Product Type
3.5 Artemisinin Market Competitive Situation and Trends
3.5.1 Artemisinin Market Concentration Rate
3.5.2 Artemisinin Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion

Chapter 4 Global Artemisinin Production, Revenue (Value) by Region (2012-2017)
4.1 Global Artemisinin Production by Region (2012-2017)
4.2 Global Artemisinin Production Market Share by Region (2012-2017)
4.3 Global Artemisinin Revenue (Value) and Market Share by Region (2012-2017)
4.4 Global Artemisinin Production, Revenue, Price and Gross Margin (2012-2017)
4.5 North America Artemisinin Production, Revenue, Price and Gross Margin (2012-2017)
4.6 Europe Artemisinin Production, Revenue, Price and Gross Margin (2012-2017)
4.7 China Artemisinin Production, Revenue, Price and Gross Margin (2012-2017)
4.8 Japan Artemisinin Production, Revenue, Price and Gross Margin (2012-2017)
4.9 Southeast Asia Artemisinin Production, Revenue, Price and Gross Margin (2012-2017)
4.10 India Artemisinin Production, Revenue, Price and Gross Margin (2012-2017)

Chapter 5 Global Artemisinin Supply (Production), Consumption, Export, Import by Regions (2012-2017)
5.1 Global Artemisinin Consumption by Regions (2012-2017)
5.2 North America Artemisinin Production, Consumption, Export, Import by Regions (2012-2017)
5.3 Europe Artemisinin Production, Consumption, Export, Import by Regions (2012-2017)
5.4 China Artemisinin Production, Consumption, Export, Import by Regions (2012-2017)
5.5 Japan Artemisinin Production, Consumption, Export, Import by Regions (2012-2017)
5.6 Southeast Asia Artemisinin Production, Consumption, Export, Import by Regions (2012-2017)
5.7 India Artemisinin Production, Consumption, Export, Import by Regions (2012-2017)

Chapter 6 Global Artemisinin Production, Revenue (Value), Price Trend by Type
6.1 Global Artemisinin Production and Market Share by Type (2012-2017)
6.2 Global Artemisinin Revenue and Market Share by Type (2012-2017)
6.3 Global Artemisinin Price by Type (2012-2017)
6.4 Global Artemisinin Production Growth by Type (2012-2017)

Chapter 7 Global Artemisinin Market Analysis by Application
7.1 Global Artemisinin Consumption and Market Share by Application (2012-2017)
7.2 Global Artemisinin Consumption Growth Rate by Application (2012-2017)
7.3 Market Drivers and Opportunities
7.3.1 Potential Applications
7.3.2 Emerging Markets/Countries

Chapter 8 Global Artemisinin Manufacturers Analysis
8.1 Sanofi
8.1.1 Company Basic Information, Manufacturing Base and Competitors
8.1.2 Product Type, Application and Specification
8.1.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.1.4 Business Overview
8.2 KPC Pharmaceuticals, Inc
8.2.1 Company Basic Information, Manufacturing Base and Competitors
8.2.2 Product Type, Application and Specification
8.2.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.2.4 Business Overview
8.3 Guangxi xiancaotang pharmaceutical Co., LTD
8.3.1 Company Basic Information, Manufacturing Base and Competitors
8.3.2 Product Type, Application and Specification
8.3.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.3.4 Business Overview
8.4 Guilin Pharmaceutical Co., Ltd
8.4.1 Company Basic Information, Manufacturing Base and Competitors
8.4.2 Product Type, Application and Specification
8.4.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.4.4 Business Overview
8.5 Kerui nanhai Pharmaceutical Co., Ltd
8.5.1 Company Basic Information, Manufacturing Base and Competitors
8.5.2 Product Type, Application and Specification
8.5.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.5.4 Business Overview
8.6 Shanghai Natural Bio-engineering Co., Ltd
8.6.1 Company Basic Information, Manufacturing Base and Competitors
8.6.2 Product Type, Application and Specification
8.6.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.6.4 Business Overview
8.7 PIDI Standard
8.7.1 Company Basic Information, Manufacturing Base and Competitors
8.7.2 Product Type, Application and Specification
8.7.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.7.4 Business Overview
8.8 Novanat Bioresource Co., Ltd
8.8.1 Company Basic Information, Manufacturing Base and Competitors
8.8.2 Product Type, Application and Specification
8.8.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.8.4 Business Overview
8.9 CATKHANH CO., Ltd
8.9.1 Company Basic Information, Manufacturing Base and Competitors
8.9.2 Product Type, Application and Specification
8.9.3 Production, Revenue, Price and Gross Margin (2012-2017)
8.9.4 Business Overview
…

Chapter 9 Artemisinin Manufacturing Cost Analysis
9.1 Artemisinin Key Raw Materials Analysis
9.1.1 Key Raw Materials
9.1.2 Price Trend of Key Raw Materials
9.1.3 Key Suppliers of Raw Materials
9.1.4 Market Concentration Rate of Raw Materials
9.2 Proportion of Manufacturing Cost Structure
9.2.1 Raw Materials
9.2.2 Labor Cost
9.2.3 Manufacturing Expenses
9.3 Manufacturing Process Analysis of Artemisinin

Chapter 10 Industrial Chain, Sourcing Strategy and Downstream Buyers
10.1 Artemisinin Industrial Chain Analysis
10.2 Upstream Raw Materials Sourcing
10.3 Raw Materials Sources of Artemisinin Major Manufacturers in 2015
10.4 Downstream Buyers

Chapter 11 Marketing Strategy Analysis, Distributors/Traders
11.1 Marketing Channel
11.1.1 Direct Marketing
11.1.2 Indirect Marketing
11.1.3 Marketing Channel Development Trend
11.2 Market Positioning
11.2.1 Pricing Strategy
11.2.2 Brand Strategy
11.2.3 Target Client
11.3 Distributors/Traders List

Chapter 12 Market Effect Factors Analysis
12.1 Technology Progress/Risk
12.1.1 Substitutes Threat
12.1.2 Technology Progress in Related Industry
12.2 Consumer Needs/Customer Preference Change
12.3 Economic/Political Environmental Change

Chapter 13 Global Artemisinin Market Forecast (2017-2021)
13.1 Global Artemisinin Production, Revenue Forecast (2017-2021)
13.2 Global Artemisinin Production, Consumption Forecast by Regions (2017-2021)
13.3 Global Artemisinin Production Forecast by Type (2017-2021)
13.4 Global Artemisinin Consumption Forecast by Application (2017-2021)
13.5 Artemisinin Price Forecast (2017-2021)

Chapter 14 Appendix

                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields


Related Reports

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 63 | Code : MRS-152442 | 2000

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape. Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amo Read more

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 120 | Code : MRS-152441 | 2000

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pa Read more

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 98 | Code : MRS-152440 | 2000

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape. Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapi Read more

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 39 | Code : MRS-152439 | 3500

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2017 Summary According to the recently published report 'P2X Purinoceptor 7 - Pipeline Review, H2 2017'; P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated i Read more

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 72 | Code : MRS-152438 | 3500

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017 Summary Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia. Smoothened Homolog (Protein Gx Read more

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 39 | Code : MRS-152437 | 3500

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2017 Summary Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 o Read more

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 34 | Code : MRS-152436 | 3500

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2017 Summary According to the recently published report 'G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2017'; G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) pipeline Target constitutes close to 8 molecules. Out of Read more

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 48 | Code : MRS-152435 | 3500

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Pipeline Review, H2 2017 Summary Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitt Read more

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 51 | Code : MRS-152434 | 3500

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2017 Summary Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Targe Read more

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 45 | Code : MRS-152433 | 3500

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2017 Summary According to the recently published report 'Ephrin Type B Receptor 4 - Pipeline Review, H2 2017'; Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 2 molecules are developed by companies and remaining Read more

Single User | $(USD)2800 View Pricing